sigmoid.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
A social space for people researching, working with, or just interested in AI!

Server stats:

594
active users

John Urbanik

Enjoying this paper from the Sheltzer lab - it reads a bit like a group of biologists playing detective. They start with a theory that is necessary for the malignancy of some cancer lines, and then trace this all the way to showing some very tight links to MDM4. They even propose a therapeutic using differential sensitivity between disomic and trisomic cells.

biorxiv.org/content/10.1101/20

bioRxivOncogene-like addiction to aneuploidy in human cancersMost cancers exhibit aneuploidy, but its functional significance in tumor development is controversial. Here, we describe ReDACT (Restoring Disomy in Aneuploid cells using CRISPR Targeting), a set of chromosome engineering tools that allow us to eliminate specific aneuploidies from cancer genomes. Using ReDACT, we created a panel of isogenic cells that have or lack common aneuploidies, and we demonstrate that trisomy of chromosome 1q is required for malignant growth in cancers harboring this alteration. Mechanistically, gaining chromosome 1q increases the expression of MDM4 and suppresses TP53 signaling, and we show that TP53 mutations are mutually-exclusive with 1q aneuploidy in human cancers. Thus, specific aneuploidies play essential roles in tumorigenesis, raising the possibility that targeting these "aneuploidy addictions" could represent a novel approach for cancer treatment. ### Competing Interest Statement J.C.S. is a co-founder of Meliora Therapeutics, a member of the advisory board of Surface Ventures, and an employee of Google, Inc. This work was performed outside of her affiliation with Google and used no proprietary knowledge or materials from Google. J.M.S. has received consulting fees from Merck, Pfizer, Ono Pharmaceuticals, and Highside Capital Management, is a member of the advisory board of Tyra Biosciences and the Chemical Probes Portal, and is a co-founder of Meliora Therapeutics.

The methods are fun too - some very clever use of CRISPR to truncate single copies of particular chromosome arms.